Nevimune Nevirapine 200mg Tablets

Q1: What is Nevimune (Nevirapine 200mg) used for?

Nevimune is an NNRTI used as the third agent in HIV combination therapy with a dual NRTI backbone. It is widely used in resource-limited settings as a cost-effective, well-studied NNRTI option for treatment-naive and some treatment-experienced patients.

Q2: What is the mandatory 14-day lead-in period?

Nevirapine MUST be started at 200mg once daily for 14 days (lead-in phase) before increasing to 200mg twice daily (full dose). This allows hepatic CYP3A4 enzyme induction to occur gradually, reducing the risk of severe rash and hepatotoxicity from ~30% to approximately 5%.

Q3: What happens if the lead-in period is skipped?

Skipping the 14-day lead-in dramatically increases the risk of severe rash (including Stevens-Johnson syndrome) and hepatotoxicity. If interrupted for more than 7 days, the lead-in must be restarted from the beginning.

Q4: Which patients have the highest risk of Nevirapine hepatotoxicity?

Women with CD4 counts above 250 cells/mm³ and men with CD4 counts above 400 cells/mm³ are at significantly higher hepatotoxicity risk (up to 12-fold for women). Many guidelines contraindicate Nevirapine in these patients — confirm CD4 count before starting.

Q5: What are the most common side effects?

Rash (in ~5–15% after lead-in, commonly in the first 6 weeks), nausea, headache, fatigue, and elevated liver enzymes. Rash is the most common reason for early discontinuation.

Q6: How should rash be evaluated during Nevimune therapy?

Mild rash (small area, no fever, no involvement of mucous membranes) during the lead-in phase may be monitored while continuing Nevirapine. Severe rash (widespread, blistering, involving mouth/eyes), rash with fever, or rash after the 6-week window = STOP IMMEDIATELY and seek emergency care.

Q7: What is Stevens-Johnson syndrome?

SJS is a rare but life-threatening skin and mucous membrane reaction causing blistering, skin peeling, and systemic illness. It requires immediate hospitalisation and cessation of Nevirapine. Patients who develop SJS must never receive Nevirapine again.

Q8: What liver monitoring is required with Nevimune?

Liver function tests (ALT, AST) must be checked at baseline, at 2 weeks, 4 weeks, and 8 weeks after starting, then every 3 months. Significant ALT elevation (>5x ULN) or any hepatitis symptoms require immediate discontinuation.

Q9: What drug interactions affect Nevimune?

Nevirapine is a moderate CYP3A4 inducer — it reduces levels of many drugs including hormonal contraceptives (use backup contraception), some PIs, and certain antibiotics. It also reduces methadone levels in patients on opioid substitution therapy.

Q10: Can Nevirapine be used during pregnancy?

Nevirapine has been used in pregnancy, but the CD4-dependent hepatotoxicity risk applies to pregnant women too. Many guidelines now prefer Dolutegravir-based regimens in pregnancy. Where Nevirapine is used, strict liver monitoring is essential.

Q11: How should Nevimune 200mg be stored?

Store at room temperature away from light and moisture. Keep in original packaging out of reach of children.

Q12: Do I need a prescription?

Yes. Nevirapine requires specialist HIV prescribing with mandatory CD4 count screening before initiation, lead-in period planning, and close liver and rash monitoring.